Share on LinkedInShare on LinkedIn

ARTICLE · 05 OCTOBER 2017

Intellectual Property Weekly Abstracts Bulletin — Week Of October 2, 2017

Borden Ladner Gervais LLP
Borden Ladner Gervais LLP
Contributor
Borden Ladner Gervais LLP

Borden Ladner Gervais LLP

With over 750 lawyers, intellectual property agents and other professionals, BLG services...

View firm profile
Explore more from Borden Ladner Gervais LLP

This is an application pursuant to the Patented Medicines (Notice of Compliance) Regulations.

CanadaIntellectual Property

Patent Decisions

Order of prohibition granted in respect of crystalline form I ODV Succinate
Pfizer Canada Inc. v. Apotex Inc., 2017 FC 774

Drug: PRISTIQ o-desmethyl-venlafaxine ("ODV")

This is an application pursuant to the Patented Medicines (Notice of Compliance) Regulations. The Court began by noting a related decision in which a different second person sent a separate Notice of Allegation making different allegations. The Court issued an order of prohibition.

The patent relates to Form I ODV succinate, which the Court accepted is a novel composition of matter. Venlafaxine metabolizes into ODV, and was previously patented and approved to treat depression. The Court set out the invention story, including the experimentation with ODV fumarate and forming a pro-drug.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from